For any questions relating to the Annual Conference, please contact the conference office below:
Wheldon Events & Conferences
93 Watling Street, Bridgtown,
Cannock, Staffordshire WS11 0BG
T: +44 (0) 1543 503 322
F: +44 (0) 1543 466 890
"...As a current medical student undertaking a summer research project investigating the barriers associated with the implementation of familial hypercholesterolaemia in Scotland, I found the conference both enjoyable and incredibly helpful to see how these problems are being addressed not just in Scotland but across the world. The conference also allowed me to present a poster to an audience of experts in the field of lipidology, and despite not winning any awards it was a fantastic learning opportunity... I am confident that the experience I gained will benefit both my project and my future medical career."
Abstracts of Free Communications
Friday 6 July 2018
08:35 - 09:35
Deadline for travel grant applications: CLOSED
Judging panel: tbc
USABILITY OF A WEBTOOL TO ASSIST DECISIONS ON GENOTYPING FOR FAMILIAL HYPERCHOLESTEROLAEMIA – RESULTS FROM A CLINICAL PILOT
Ashfield-Watt PAL*, Haralambos K, Sharif B, McDowell IFW.
FH Wales Research Team, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, CF14 4XN
AUDIT OF PCSK9 INHIBITOR PRESCRIBING IN THE NORTH EAST OF ENGLAND
Banerjee P1*, Neely RDG1, Pattman S2, Artham.S3, Carey P3
1Department of Blood Sciences, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
2Department of Blood Sciences, Northumbria Healthcare NHS Foundation Trust, UK
3Department of Endocrinology, City Hospitals Sunderland Foundation Trust
SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES
Bellary S1*, Jodar E2, Seufert J3, Damgaard LH4, Gaarsdal Holst A4, Leiter L.5
1Aston University, Birmingham, UK; 2Universidad Europea de Madrid, Madrid, SPAIN; 3University of Freiburg, Freiburg, Germany; 4Novo Nordisk, Soborg, DENMARK; 5Li Ka Shing Knowledge Institute and University of Toronto, ON, CANADA
HYPERCHOLESTEROLEMIA WITH LOW VERSUS HIGH LIKELIHOOD OF POLYGENIC ORIGIN: A SINGLE CENTRE EXPERIENCE
A. David*1, J. Cegla1, S. Walji1, B. Jones1, S. Haboosh1, F. De Lorenzo1, J. Scott1, G.R. Thompson1
1 Lipid Clinic, Hammersmith Hospital, Imperial NHS Trust, London, UK
PATIENT EXPERIENCE AT A DEDICATED MULTIDISCIPLINARY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) CLINIC ENCOMPASSING CARDIOVASCULAR RISK ASSESSMENT AND MANAGEMENT. A NEW MODEL OF CARE?
Goyale A1*, Misas MG 2, Roccarina D2, Nair DR 1 and Tsochatzis E2
Royal Free London NHS Foundation Trust, London, NW3 2QG
UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London
THE IMPACT OF SOCIO-ECONOMIC STATUS ON CASE FINDING FOR FAMILIAL HYPERCHOLESTEROLAEMIA
L. Gritzmacher1*, K. Haralambos2, P. Downie1, G. Bayly1.
1 Department of Biochemistry, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
2 BHF FH Register (PASS) Coordinator, Cardiff University, Cardiff, UK
UNUSUAL PRESENTATION OF RHABDOMYOLYSIS AFTER CO-ADMINISTRATION OF STATIN AND CLARITHROMYCIN
O. Kirresh*, C. Lunken
Department of Endocrinology, University College London Hospitals, UK.
DUAL PATHOLOGY FOR PANCREATITIS IN PREGNANCY
O. Kirresh*, U. Srirangalingam, C. Lunken
Department of Endocrinology, University College London Hospitals, UK.
SETTING UP A REGIONAL FH SERVICE; A SUMMARY OF THE ACHIEVEMENTS AND CHALLENGES
K Mitchell*1, J Webster1, C Tuson2, C Burton4, P Sutton3, R Dunn3, D Chandrajay2, D Narayanan3, M Mansfield4, J Barth4, A Bandyopadhyay2, K Haralambos5 B Power6 J Jessop6
1Calderdale and Huddersfield NHS Trust, England; 2York Teaching Hospitals NHS Foundation Trust, England; 3Hull Teaching Hospitals NHS Trust, England; 4Leeds Teaching Hospitals NHS Trust, England; 5Cardiff and Vale University Hospitals Board, Wales; 6 Yorkshire and Humber Strategic Clinical Network
AN EXPERIENCE OF DEDICATED FH SERVICE IMPLEMENTATION IN HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST
Paula Sutton1, Rachel Dunn1, Rob Desborough1, Mohammed Malik2, Aditi Bandyopadhyay3, Kate Haramblos4, Deepa Narayanan1.
1 Hull and East Yorkshire Hospitals NHS Trust
2 North Lincolnshire and Goole Hospitals NHS Trust
3York Teaching Hospitals NHS Trust
4PASS coordinator, Wales.
EFFECT OF COMBINATION THERAPY WITH PCSK9 INHIBITORS AND LIPOPROTEIN APHERESIS
A Pottle*, C Browne, E Neves, M Barbir
Cardiology Department, Harefield Hospital, Royal Brompton & Harefield NHS Foundation Trust, London, UK
THE EFFECT OF EXERCISE TRAINING ON LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Gina Wood, Neil A. Smart
University of New England, Armidale, NSW Australia 2350.
UNMODERATED POSTER SESSION:
A QUALITY IMPROVEMENT PROJECT: OPTIMISING LIPID LOWERING DIETARY ADVICE VIA GROUP EDUCATION SESSIONS FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE
D. Barrese1*, A. Lang1, M. Crook2*, A. Nassor1*, D. Gray1, M. Kagka1*
1Department of Nutrition and Dietetics, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
2Consultant in Clinical Biochemistry and Metabolic Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
A CASE OF RESISTANCE TO PCSK9 INHIBITOR TREATMENT
1Department of Chemical Pathology, Lister Hospital, Stevenage, SG1 4AB, UK
METABOLIC SYNDROME CRITERIA AND SUBCLINICAL VASCULAR DISEASE IN ELDERLY MEN
EA Ellins1*, LT Lennon2, O Papacosta2, SG Wannamethee2, PH Whincup3, JP Halcox1
1Institute of Life Sciences, Swansea University Medical School,
2UCL Department of Primary Care & Population Health, UCL Medical School,
3Division of Population Health Sciences and Education, Population Health Research Institute, St George’s University of London
LCAT DEFICIENCY- A CASE REPORT
Jain A*, Hoshi N, Defesche J 1, Nair D R
Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, NW3 2QG.
1Molecular Diagnostic Laboratory, Department of Vascular Medicine, Academic Medical centre, Amsterdam, NL-1105 AZ, The Netherlands.
PCSK9 INHIBITORS- FITTING THEM INTO ROUTINE PRACTICE IN A LIPID CLINIC
Jain A*, Harvey D, oshi N, Sharifi M, Dhalla S1, Nair DR
Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust,London, NW3 2QG. 1Pharmacy, Royal Free London NHS Foundation Trust, London, NW3 2QG.
EXAMINING THE BURDEN OF ILLNESS IN PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME: RESULTS OF THE IN-FOCUS STUDY, UNITED KINGDOM RESPONDENTS
Handrean Soran1, Michael Stevenson2, Karren Williams2, Brant Hubbard2, Richard Jones*2, Basil Issa3
1Manchester University Hospital NHS Trust, Manchester, UK; 2Akcea Therapeutics Inc., Cambridge, MA, USA; 3Department of Endocrinology, University Hospital of South Manchester, Wythenshawe, UK
SITOSTEROLAEMIA AS A CAUSE OF TENDON XANTHOMATA IN A PATIENT WITH HYPERLIPIDAEMIA
Ian McDowell*1,3 Emily Capener2 Heather Wheatley3 Peter Clayton4 Andrew Goringe5
1 Cardiff University School of Medicine; 2 Dept of Dietetics, Cardiff and Vale University Health Board; 3 Dept of Medical Biochemistry and Immunology, Cardiff and Vale University Health Board
4 UCL Great Ormond Street Institute of Child Health; 5 Dept of Haematology, Cardiff and Vale University Health Board
MEASUREMENT OF ABSORPTION STEROLS IN PATIENTS WITH HYPERCHOLESTEROLAEMIA: IMPROVED DIAGNOSTIC PERFORMANCE WHEN STEROL/CHOLESTEROL RATIOS ARE REPORTED
A Bowron, E Middling, M Appleton, C Boot, D Neely*
Department of Blood Sciences, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
LIPID MANAGEMENT WITH PCSK9 INHIBITORS - COMBINATION OR MONOTHERAPY? EXPERIENCE FROM A TERTIARY CARDIAC CENTRE
Neves E*, Browne C, Breen J, Davis L, Hayes C, Manning S, Priestley-Barnham L, Barbir M.
Royal Brompton & Harefield NHS Foundation Trust
REVIEW AND ANALYSIS OF A SINGLE CENTRES FIRST ONE HUNDRED PATIENTS PRESCRIBED PCSK9 THERAPY
K Peers*1 S Ramachandran 2,3 A Jones 4
1 Advanced Nurse Practitioner in Department of Clinical Chemistry, Heartlands Hospital, Birmingham, England 2 Professor Metabolic Medicine, Department of Clinical Chemistry, Good Hope Hospital, Birmingham, England 3 Research in Metabolic medicine, Warwick University, Midlands, England 4 Consultant Physician in Clinical Chemistry, Heartlands Hospital, Birmingham, England
RECRUITING FAMILIAL HYPERCHOLESTEROLAEMIA (FH) PATIENTS TO THE 100,000 GENOME PROJECT. THE EXPERIENCE OF SPECIALIST NURSESIN THE WESSEX FH SERVICE
Sherman, CI*, Cazeaux, A
Wessex Familial Hypercholesterolaemia Genetics Service, Clinical Genetics, G Level, Princess Anne Hospital, Coxford Road, Southampton. SO16 5YA
Poster Presentation Prizes - £150 and £75
Two prizes will be awarded for the best healthcare professional poster free communication made at the conference.
£150 – winner
£75 – runner up
Poster "People's Choice" Prize - £100
One prize will be awarded for the best poster as nominated by conference delegates during the conference. This is your opportunity to vote for your "People's Choice" best poster. We would encourage delegates to attend during the moderated poster session on Friday morning when poster authors will be in attendance. A voting slip will be included in each delegate pack and votes can be made up until noon on Friday.
Every vote counts - please take time to view the posters.
Poster presentations will be marked by a judging panel on presentation and content.
Whilst authors must be on hand to discuss their work with the judging panel during this time the posters will be available for delegates to view throughout the conference period.
Presenting authors must be ready with 3-4 bullet points explaining their poster which will be followed by 2 minutes discussion with the judges.
Link to prize and award information
Presented moderated abstracts will be published after the conference on line in Atherosclerosis Supplements.
INFORMATION TO POSTER AUTHORS:
Poster board size:
1m (left to right) x 2m (top to bottom) – portrait - (100cm wide x 200cm deep)
THUS PLEASE ENSURE:
1. Your poster is printed to portrait and NOT landscape size.
2. That your poster is printed to A0 size (841mm wide x 1189 mm deep).
Velcro will be provided for your use. NO pins, blue-tak or cellotape can be used as these will damage the panels and you will be charged for any damage incurred.
You may erect your poster on Wednesday from 1500 hours.
Posters must be ready for viewing from 1900 hours.
Please refer to the allocated board number as detailed within the programme book which will be handed to all attendees from the registration desk.
Your poster must be removed by 1400 hours on Friday.
Any posters remaining after this time will not be returned to the authors but destroyed.